Ultrasound-based transient elastography provides excellent diagnostic accuracy in identifying cirrhosis due to recurrent hepatitis C following liver transplantation.
Ultrasound-based transient elastography (ET) provides excellent diagnostic accuracy in identifying cirrhosis due to recurrent hepatitis C (HCV) following liver transplantation, according to Mayo Clinic researchers. This was the result of a study published in the March issue of Liver Transplantation.
Currently, doctors rely on biopsies to detect progression of cirrhosis of the liver. Liver biopsies are invasive and are not always very accurate, said Jayant Talwalkar, MD, one of the study authors. In an effort to determine if the non-invasive ultrasound-based ET could provide better diagnosis, the researchers performed a systematic review and diagnostic accuracy meta-analysis of studies that compared ET to liver biopsies in detecting hepatic fibrosis post-transplant.
Patients who receive liver transplants and who are HCV RNA-positive at the time, are at risk of re-infection with HCV, so monitoring the liver is essential.
Six studies were identified; five evaluated significant fibrosis and five assessed cirrhosis. Analysis of detecting fibrosis showed that ET had an 83 percent for both sensitivity and specificity. For detecting cirrhosis, sensitivity was 98 percent and specificity 84 percent.
These findings indicated that the ultrasound-based procedure is very accurate compared with biopsies. “Further studies that confirm our results could highlight the importance of ET as a diagnostic tool for liver transplant recipients infected with HCV,” said Dr. Talwalkar.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.